Medical cannabis — prescription, access, reimbursement

Since 1 August 2022 Swiss physicians can prescribe medical cannabis without a special FOPH permit — a milestone that has expanded access from a few hundred to several thousand patients. This hub walks through the entire pathway: first consultation, indication review (chronic pain, MS spasticity, chemotherapy-induced nausea, refractory epilepsy, palliative care), prescription issuance, pickup at specialised pharmacies, and the complex question of reimbursement. Health insurers only cover on a case-by-case basis after application; typical out-of-pocket cost is CHF 300–800/month depending on the formulation (Sativex, dronabinol, magistral oils, dried flower). We compare flower vs extract therapy, document the licensed Swiss producers, and show how patients can obtain complementary access through the pilot framework — including pointers to specialised medical networks.

Since the 2022 Narcotics Act revision the FOPH's special permit is no longer required. We detail the ordinance, document preparations (Sativex, Epidyolex, Bedrocan, Bediol) and the current basic-insurance reimbursement practice for chronic pain, MS spasticity and CINV.

Definition and context

Medical cannabis refers to standardized cannabis-based medicines—such as flowers, extracts, dronabinol, or finished medicinal products—obtained from pharmacies with a medical prescription.

The situation in Switzerland

Since 1 August 2022, the FOPH exceptional authorization is no longer required, allowing doctors to prescribe medical cannabis directly. However, cost coverage by basic health insurance is not automatically guaranteed and is evaluated on a case-by-case basis, which remains the most common hurdle for patients.

What this means in practice

The process always starts with your treating physician; self-medication with black-market products is not a viable alternative, legally or qualitatively. Regarding treatment costs, it is advisable to obtain a prior written cost-coverage commitment from your health insurance provider before beginning therapy.

Frequently asked questions

Do I still need an FOPH authorization?

No. Since 1 August 2022, doctors can prescribe it directly without an exceptional authorization.

Does health insurance cover medical cannabis?

Not as a general rule. Coverage is reviewed on a case-by-case basis; obtaining a cost-coverage commitment before starting therapy provides clarity.

What preparations are available?

Standardized flowers, oils, and extracts, as well as finished medicinal products. Your treating doctor will determine which form is suitable for you.

Background and development

Prior to August 2022, access to medical cannabis containing over 1% THC required an exceptional individual permit from the Federal Office of Public Health (FOPH/BAG), a bureaucratic hurdle that restricted treatment to a small cohort. The landmark revision of the Narcotics Act (BetmG) transferred regulatory oversight of medical prescriptions directly to doctors, while Swissmedic remains responsible for licensing domestic cultivation, manufacturing, and distribution of medical-grade cannabis. Today, Switzerland represents a highly regulated medical market where pharmacies dispense standardized, quality-controlled formulations. Concurrently, the FOPH-approved pilot studies (such as those in Zurich, Basel, Bern, Lausanne, and Geneva) explore regulated adult-use sales, but these remain strictly separated from the medical prescription framework governed by the BetmG. This dual-track approach reflects Switzerland’s progressive yet structured shift toward evidence-based cannabis policy, ensuring patients access certified pharmaceutical-grade products under strict clinical supervision.

Distinctions and misconceptions

It is crucial to distinguish medical cannabis from over-the-counter CBD products and recreational cannabis. In Switzerland, CBD products with less than 1% THC are legal for general sale but are classified as cosmetics, chemicals, or tobacco substitutes, not medicines. Conversely, medical cannabis therapies often exceed the 1% THC limit and are strictly prescription-only. A common misconception is that holding a medical prescription exempts patients from Swiss traffic laws. In reality, the legal driving limit of 1.5 micrograms of THC per litre of blood applies to everyone, and patients must undergo a medical assessment regarding their fitness to drive. Furthermore, participating in regional adult-use pilot studies in Zurich, Basel, or Geneva is not the same as receiving medical treatment; these scientific pilots are designed to study regulated non-medical supply chains for healthy adults, whereas medical pathways focus strictly on therapeutic indications under continuous clinical observation.

Decision guide for Switzerland

When considering medical cannabis in Switzerland, an adult must first evaluate their clinical eligibility with a qualified physician. Essential steps include obtaining an official diagnosis for recognized indications, discussing flower versus extract options, and securing a written cost-coverage commitment from your health insurer before starting therapy to avoid out-of-pocket expenses, which typically range from CHF 300 to CHF 800 monthly. You should completely avoid self-medicating with unregulated black-market products. Not only do illicit products lack standardized active ingredient profiles, but carrying them also risks a CHF 100 fixed penalty if caught with up to 10 grams of non-medical THC cannabis. Opt instead for a legal medical prescription dispensed through licensed pharmacies, or look into joining a specialized medical network. For healthy adults seeking non-medical access, Swiss residency and participation in official FOPH-approved municipal pilot studies remain the sole legal alternatives.

Can I legally drive in Switzerland while undergoing medical cannabis therapy?

Driving with THC in your system is strictly regulated in Switzerland. The legal limit is 1.5 micrograms of THC per litre of blood. While medical patients are not exempt from this limit, your treating physician can perform a driving aptitude assessment. If they confirm your fitness to drive under a stable dosage, Swiss authorities may grant an exceptional permit. However, driving while impaired is always prohibited.

What is the legal risk if I buy non-prescription cannabis for self-medication?

Self-medicating with unauthorized cannabis carries significant legal risks. In Switzerland, possession of up to 10 grams of cannabis containing over 1% THC for personal consumption is illegal and punishable by a CHF 100 fixed penalty. More importantly, black-market products are not quality-tested or standardized. To ensure safety and legality, you should always obtain a medical prescription to purchase certified pharmaceutical-grade cannabis directly from a licensed Swiss pharmacy.

Explore this topic further

These guides explain the background and address practical questions in the Swiss context.

Key figures

  • 2022 — medical cannabis allowed in CH without federal special permit (BetmG-Revision · Bundesrat 01.08.2022)
  • 8’000+ — active medical-cannabis prescriptions in Switzerland (SGCM · Bericht 2024)

Current research

  • Medical Cannabis — Swiss guidelines — SGCM / SSCM, Schweizerische Ärztezeitung · 2024

Datasets on this topic